Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 0.61 |
| ▸ | ABAT | P80404 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459879 | 1.00 | OAT (0.61) | OATABATKDM4EMEN1HPGD | |
| Hydrochloric Acid SCHEMBL22440734 | 0.99 | OAT (0.60) | OATABATKDM4EMEN1HPGD | |
| Hydrochloric Acid SCHEMBL22440721 | 0.99 | OAT (0.60) | OATABATKDM4EMEN1HPGD | |
| SCHEMBL22459682 | 0.87 | OAT (0.60) | OATABAT | |
| SCHEMBL22459681 | 0.85 | OAT (0.57) | OATABAT | |
| SCHEMBL22459683 | 0.85 | OAT (0.57) | OATABAT | |
| SCHEMBL22459885 | 0.83 | OAT (0.76) | OATABAT | |
| SCHEMBL22459920 | 0.83 | OAT (0.76) | OATABAT | |
| SCHEMBL22460134 | 0.82 | OAT (0.69) | OATABAT | |
| SCHEMBL22459893 | 0.82 | OAT (0.69) | OATABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203596-B2 | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity | NORTHWESTERN UNIVERSITY (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203596-B2 | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity | NORTHWESTERN UNIVERSITY (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200299296-A1 | ANALOGS OF 3-AMINO-4-(PROPAN-2-YLIDENE)CYCLOPENTANE-1-CARBOXYLIC ACID AND USES THEREOF FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH ORNITHINE AMINOTRANSFERASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299296-A1 | ANALOGS OF 3-AMINO-4-(PROPAN-2-YLIDENE)CYCLOPENTANE-1-CARBOXYLIC ACID AND USES THEREOF FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH ORNITHINE AMINOTRANSFERASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299296-A1 | ANALOGS OF 3-AMINO-4-(PROPAN-2-YLIDENE)CYCLOPENTANE-1-CARBOXYLIC ACID AND USES THEREOF FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH ORNITHINE AMINOTRANSFERASE ACTIVITY | OAT, OTC, GOT2 | OAT 1/4885ABAT 9/4885KDM4E 4036/4885 |
| US-11203596-B2 | Analogs of 3-amino-4-(propan-2-ylidene)cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity | OAT, OTC, GOT2 | OAT 1/4885ABAT 9/4885KDM4E 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.